Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019028266) HEPATITIS B NANOPARTICLE-BASED VACCINE FOR INFLUENZA VIRUS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/028266 International Application No.: PCT/US2018/045032
Publication Date: 07.02.2019 International Filing Date: 02.08.2018
IPC:
A61K 39/12 (2006.01) ,A61P 31/16 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
12
Viral antigens
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12
Antivirals
14
for RNA viruses
16
for influenza or rhinoviruses
Applicants:
THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES [US/US]; Office of Technology Transfer, National Institutes of Health 6011 Executive Blvd., Suite 325, MSC 7660 Bethesda, Maryland 20892-7660, US
Inventors:
HARRIS, Audray K.; US
MCCRAW, Dustin M.; US
Agent:
STERN, Richard J.; US
Priority Data:
62/540,47402.08.2017US
Title (EN) HEPATITIS B NANOPARTICLE-BASED VACCINE FOR INFLUENZA VIRUS
(FR) VACCIN À BASE DE NANOPARTICULES D'HÉPATITE B POUR LE VIRUS DE LA GRIPPE
Abstract:
(EN) Fusion proteins comprising one or more portions of hepatitis virus core antigen (HBcAg) fused to immunogenic portions of influenza virus hemagglutinin (HA) protein, and nanoparticles (virus-like particles) formed from such proteins, nucleic acid molecules encoding such proteins, methods of making such nanoparticles, methods of using the disclosed nanoparticles to vaccinate an individual against influenza virus, and antibodies elicited by vaccination of a mammal with the disclosed nanoparticles.
(FR) La présente invention concerne des protéines de fusion comprenant une ou plusieurs parties de l'antigène capsidique du virus de l'hépatite (HBcAg) qui sont fusionnées à des parties immunogènes de la protéine hémagglutinine (HA) du virus de la grippe, et des nanoparticules (particules pseudo-virales) formées à partir de telles protéines, des molécules d'acide nucléique codant pour de telles protéines, des procédés de fabrication de telles nanoparticules, des procédés d'utilisation des nanoparticules décrites pour vacciner un individu contre le virus de la grippe, et des anticorps produits par vaccination d'un mammifère avec les nanoparticules décrites.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)